Dr. Eli Gabayan
Claim this profileGSK Investigational Site
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
3 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Eli Gabayan is currently running
Belantamab Mafodotin
for Multiple Myeloma
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.
Recruiting1 award Phase 111 criteria
Belantamab Mafodotin
for Multiple Myeloma
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation ) and have either normal or impaired renal functions. The study will consist of two parts: part 1 will include participants with normal/mildly impaired renal function and severe renal impairment and part 2 will include participants with end-stage renal disease (ESRD), where participants are either not undergoing or require hemodialysis. Participants will be administered belantamab mafodotin at a dose of 2.5 milligram per kilogram (mg/kg) intravenously once in three weeks (Q3W) dosing in Part 1. Based on the Part 1 Safety/Pharmacokinetic (PK) data, Part 2 participants will be administered the dose of either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose). Participants will be treated with belantamab mafodotin monotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. This study will include a screening phase, treatment phase, follow-up phase and a post analysis continued treatment (PACT) phase . The total duration of the study is approximately up to 48 months.
Recruiting1 award Phase 110 criteria
More about Eli Gabayan
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Eli Gabayan has experience with
- NBF-006
- Belantamab Mafodotin
- Belantamab Mafodotin
Breakdown of trials Eli Gabayan has run
Plasma Cell Neoplasms
Colorectal Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eli Gabayan specialize in?
Eli Gabayan focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Eli Gabayan currently recruiting for clinical trials?
Yes, Eli Gabayan is currently recruiting for 2 clinical trials in Beverly Hills California. If you're interested in participating, you should apply.
Are there any treatments that Eli Gabayan has studied deeply?
Yes, Eli Gabayan has studied treatments such as NBF-006, Belantamab mafodotin, Belantamab Mafodotin.
What is the best way to schedule an appointment with Eli Gabayan?
Apply for one of the trials that Eli Gabayan is conducting.
What is the office address of Eli Gabayan?
The office of Eli Gabayan is located at: GSK Investigational Site, Beverly Hills, California 90211 United States. This is the address for their practice at the GSK Investigational Site.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.